Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|April 5, 2016
[Quantitative Decision Making in Drug Development: Pharmacometrics]Akiyuki Suzuki
Clinical and Translational Science|May 8, 2019
Does Industry-Conducted All-Case Surveillance of Newly Approved Oncology Drugs Contribute to the Revision of Package Inserts in Japan?Akiyuki Suzuki, Hitoshi Sato, Yasutsuna Sasaki
Animals : an Open Access Journal From MDPI|August 29, 2024
Assessment of Captive Environment for Oriental Small-Clawed Otters (<i>Aonyx cinereus</i>) in Otter Cafés in JapanNana Ushine, Ayu Kamitaki, Akiyuki Suzuki, et al.
International Journal of Clinical Pharmacology and Therapeutics|September 25, 2019
Pharmacokinetics and exploratory efficacy biomarkers of bococizumab, an anti-PCSK9 monoclonal antibody, in hypercholesterolemic Japanese subjects
Koutaro Yokote, Akiyuki Suzuki, Yinhua Li, et al.
Organic Letters|December 6, 2002
A new strategy toward the total synthesis of stachyflin, a potent anti-influenza A virus agent: concise route to the tetracyclic core structureMari Nakatani, Masahiko Nakamura, Akiyuki Suzuki, et al.
British Journal of Clinical Pharmacology|February 3, 2022
Population pharmacokinetics of tanezumab following intravenous or subcutaneous administration to patients with osteoarthritis or chronic low back painSatoshi Shoji, Akiyuki Suzuki, Puneet Gaitonde, et al.
International Journal of Clinical Pharmacology and Therapeutics|December 8, 2025
Population pharmacokinetics of tofacitinib in patients with active ankylosing spondylitisShinichi Tsuchiwata, Akiyuki Suzuki, Qiang Wang, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 20, 2023
Prediction of relative change in free nerve growth factor following subcutaneous administration of tanezumab, a novel monoclonal antibody to nerve growth factorSatoshi Shoji, Akiyuki Suzuki, Parya Nouri, et al.
Investigational New Drugs|February 9, 2011
Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patientsYutaka Fujiwara, Naomi Kiyota, Naoko Chayahara, et al.
Pharmacogenomics|November 7, 2013
Clinical impact of genetic variants of drug transporters in different ethnic groups within and across regionsChiho Ono, Hironori Kikkawa, Akiyuki Suzuki, et al.
Pageof 2